pharma · Amyotrophic Lateral Sclerosis · Pharmacokinetics · NRSN
NeuroSense Therapeutics
NeuroSense Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker NRSN. Primary therapeutic focus areas include Amyotrophic Lateral Sclerosis, Pharmacokinetics, ALS (Amyotro
Cambridge, USA HQ
2017 Founded
30 Employees
Public company Type
NRSN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 30
- Programs
- 6
- Drugs
- 6
- Patents
- 2
PrimeC
Phase 2 · small molecule · Alzheimer Disease
PrimeC for Alzheimer Disease is a Phase 2 program (small_molecule) at NeuroSense Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code NST-AD-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NeuroSense Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Alzheimer Disease
- Status
- terminated
- Trials
- 1